CN115869260A - Milk cow nipple medicated bath liquid and preparation method thereof - Google Patents
Milk cow nipple medicated bath liquid and preparation method thereof Download PDFInfo
- Publication number
- CN115869260A CN115869260A CN202310146156.XA CN202310146156A CN115869260A CN 115869260 A CN115869260 A CN 115869260A CN 202310146156 A CN202310146156 A CN 202310146156A CN 115869260 A CN115869260 A CN 115869260A
- Authority
- CN
- China
- Prior art keywords
- polyoxyethylene ether
- bath liquid
- percent
- medicated bath
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002445 nipple Anatomy 0.000 title claims abstract description 116
- 239000007788 liquid Substances 0.000 title claims abstract description 87
- 235000013336 milk Nutrition 0.000 title claims abstract description 39
- 239000008267 milk Substances 0.000 title claims abstract description 39
- 210000004080 milk Anatomy 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000004094 surface-active agent Substances 0.000 claims abstract description 106
- 229920000056 polyoxyethylene ether Polymers 0.000 claims abstract description 81
- 229940051841 polyoxyethylene ether Drugs 0.000 claims abstract description 81
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 56
- 239000010703 silicon Substances 0.000 claims abstract description 56
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 49
- 239000011630 iodine Substances 0.000 claims abstract description 49
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 39
- 229920000570 polyether Polymers 0.000 claims abstract description 39
- MWYMHZINPCTWSB-UHFFFAOYSA-N dimethylsilyloxy-dimethyl-trimethylsilyloxysilane Chemical class C[SiH](C)O[Si](C)(C)O[Si](C)(C)C MWYMHZINPCTWSB-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000463 material Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 28
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 27
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000003381 stabilizer Substances 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 4
- -1 phosphate ester Chemical class 0.000 claims description 4
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 94
- 235000013365 dairy product Nutrition 0.000 abstract description 23
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 14
- 239000006210 lotion Substances 0.000 abstract description 9
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 230000005484 gravity Effects 0.000 abstract description 3
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- 239000000701 coagulant Substances 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 66
- 230000000052 comparative effect Effects 0.000 description 54
- 235000011187 glycerol Nutrition 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 21
- 239000000600 sorbitol Substances 0.000 description 21
- 235000010356 sorbitol Nutrition 0.000 description 21
- 239000003814 drug Substances 0.000 description 16
- 210000000481 breast Anatomy 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- GWTCIAGIKURVBJ-UHFFFAOYSA-L dipotassium;dodecyl phosphate Chemical compound [K+].[K+].CCCCCCCCCCCCOP([O-])([O-])=O GWTCIAGIKURVBJ-UHFFFAOYSA-L 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000010668 complexation reaction Methods 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 7
- XUJLWPFSUCHPQL-UHFFFAOYSA-N 11-methyldodecan-1-ol Chemical compound CC(C)CCCCCCCCCCO XUJLWPFSUCHPQL-UHFFFAOYSA-N 0.000 description 6
- 150000002191 fatty alcohols Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000000536 complexating effect Effects 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000004166 Lanolin Substances 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 208000004396 mastitis Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- QZMAEZWZCGBZFK-UHFFFAOYSA-N 28-(beta-D-Glucopyranosyloxy)-28-oxoolean-12-en-3beta-yl 3-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosiduronic acid Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC(C1O)OC(C(O)=O)C(O)C1OC1OC(CO)C(O)C(O)C1O QZMAEZWZCGBZFK-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- KPJWZUAARPJYSB-UHFFFAOYSA-N glycoside C Natural products CC1(C)OC(=O)C23CCC1C2(O)CCC(C1(CCC24)C)(C)C3CCC1C2(C)CCCC4(C)COC(C(C(O)C1O)OC2C(C(O)C(CO)O2)O)OC1COC1OC(CO)C(O)C(O)C1O KPJWZUAARPJYSB-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029419 Nipple infection Diseases 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- YADZBEISHVCBSJ-UHFFFAOYSA-N [I].OCC(O)CO Chemical compound [I].OCC(O)CO YADZBEISHVCBSJ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicated bath lotion for nipples of dairy cows and a preparation method thereof, and belongs to the technical field of medicated bath lotions for animals. The cow nipple medicated bath liquid comprises the following components in percentage by weight: 0.5-5% of iodine preparation, 3-30% of isomeric tridecanol polyoxyethylene ether, 0.001-0.1% of organic silicon surfactant, 2-20% of auxiliary surfactant, 0-60% of auxiliary material and the balance of water. According to the invention, the polyether modified heptamethyltrisiloxane dimeric silicon surfactant is used as a coagulant, so that the surface tension of the medicinal bath liquid can be reduced, after the medicinal bath liquid soaks the cow nipple, the medicinal bath liquid can quickly fall to the nipple through the hydrophobic effect of silicon and the self gravity, so that the medicinal bath liquid is quickly coagulated at the cow nipple, the dosage of the cow nipple is increased, and more concentrated and thorough sterilization and disinfection are achieved inside and outside the nipple, so that the bacterial content in a milk product is reduced, and the quality of the milk product is improved.
Description
Technical Field
The invention relates to the technical field of bath lotion for veterinary use, in particular to a cow nipple bath lotion and a preparation method thereof.
Background
Cow teats are susceptible to inflammation due to long-term milking, and a cow teat medicated bath is an effective method for preventing inflammation of cow mammary gland. The medicinal bath liquid can prevent mastitis of the milk cow, and can quickly act on the milk head of the milk cow when being used as a bactericide before milk is extruded, so that various bacteria can be killed more quickly, and the quality of the milk extruded after the medicinal bath liquid is cleaned can be better.
The liquid medicine for dairy cows generally comprises a front medicine bath liquid and a rear medicine bath liquid. Before milking, the cow teats need to be soaked and sterilized by using the prodrug bath solution, and the prodrug bath solution is rinsed with clean water after the teats stay for 2-5s and then is milked. In the milking process, sterilization of the inside and outside of the nipple is an important link for reducing milk bacteria, so that the pro-drug bath lotion is required to quickly kill various pathogenic bacteria without damaging the skin, and the soaked drug bath lotion is required to be quickly condensed on the nipple of the milk, so that the pro-drug bath lotion is more concentrated on the nipple of the milk, and the concentration of the pro-drug bath lotion is favorable for improving the action effect of the bactericide.
The existing medicated bath liquid generally comprises a sterilization component and a film-forming agent, wherein the sterilization component adopts iodine preparations, quaternary ammonium salts, guanidines and the like. The traditional iodine medicated bath liquid is mostly prepared by mixing other surfactants with film-forming substances such as povidone, polyethylene glycol, saccharide derivatives, hydroxymethyl cellulose, arabic gum and the like. The medicinal bath liquid is generally used after milk is squeezed out, forms a film on the surface of a nipple of a cow, acts on the nipple of the cow for a long time, and protects the nipple for a long time, but the medicinal bath liquid is mainly used as a post-medicinal bath liquid. The prodrug bath solution is generally drained after the cow breasts are soaked for 2 to 5 seconds before milking, the prodrug bath solution forms a wall-hanging state on the surfaces of the breasts, a formed film is uniformly spread on the surfaces of the breasts and nipples and cannot be rapidly condensed on the nipples, and the content of the prodrug bath solution on the nipples is low. The pro-drug bath lotion is generally kept for 1-2min in the breasts, and the breasts are washed with clean water and then milked. Because the prodrug bath solution has short residence time at the nipple and low content at the nipple, the prodrug bath solution can not thoroughly sterilize the inside and outside of the nipple, and the bacterial content of the dairy product is still easy to increase during milking, and the risk of nipple infection is increased.
Disclosure of Invention
In order to solve the problems, the invention provides the medicated bath solution for the nipples of the dairy cows, which can be quickly condensed at the nipples before milking, so that the sterilization liquid medicine at the nipples is increased, the nipples are sterilized intensively and efficiently, the action time of the medicated bath solution is shortened, the incidence rate of mastitis of the dairy cows is reduced, and the milk production efficiency is improved.
In order to achieve the purpose, the invention is realized by the following technical scheme:
the medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 0.5-5% of iodine preparation, 3-30% of isomeric tridecanol polyoxyethylene ether, 0.001-0.1% of organic silicon surfactant, 2-20% of auxiliary surfactant, 0-60% of auxiliary material and the balance of water.
Further, the EO number of the isomeric tridecanol polyoxyethylene ether is 10-30.
Further, the organic silicon surfactant is polyether modified heptamethyltrisiloxane gemini silicon surfactant.
Further, the auxiliary surfactant is one or more of fatty alcohol-polyoxyethylene ether, betaine, alkylphenol ethoxylates, fatty amine, phosphate ester, EO and PO block surfactants.
Further, the fatty alcohol-polyoxyethylene ether in the auxiliary surfactant is any one of fatty alcohol-polyoxyethylene ether AEO-3, fatty alcohol-polyoxyethylene ether AEO-10 and fatty alcohol-polyoxyethylene ether AEO-9;
the EO and PO block surfactants are copolymers with EO numbers of 3-30.
Furthermore, the auxiliary materials comprise one or more of wetting agent, stabilizing agent and pH regulator.
Further, the stabilizer is one or more of hydroxymethyl cellulose, carboxymethyl cellulose and xanthan gum.
A preparation method of a cow nipple medicated bath liquid comprises the following steps:
(1) Adding an iodine preparation and isomeric tridecanol polyoxyethylene ether into a reaction container, wherein the reaction temperature is 50-100 ℃, and the reaction time is 0.5-3h;
(2) Adding an auxiliary surfactant, an organic silicon surfactant, an auxiliary material and water into the reaction container in the step (1), and reacting for 0.5-3h at the reaction temperature of 50-100 ℃; and finally adding a pH regulator to regulate the pH value to 6-7, and reacting for 10-30min to obtain the cow nipple medicated bath liquid.
The invention relates to a milk cow nipple medicated bath liquid and a preparation method thereof, which has the beneficial effects that:
(1) The polyether modified heptamethyltrisiloxane gemini silicon surfactant is used as a coagulant, the polyether modified heptamethyltrisiloxane gemini silicon surfactant is a novel special surfactant, the surface tension of the drug bath solution can be reduced by a very small amount, the drug bath solution can be quickly dropped to a nipple according to the self gravity of the drug bath solution when water and air in the drug bath solution are in interface contact with each other through the hydrophobic effect of silicon after the drug bath solution infiltrates the nipple of a milk cow, the drug bath solution is quickly coagulated at the nipple of the milk cow through the coagulation effect of the polyether modified heptamethyltrisiloxane gemini silicon surfactant, the dosage of the drug at the nipple of the milk cow is increased, and a more thorough sterilization and disinfection effect is achieved on the inside and outside of the nipple, so that a better protection effect is achieved on the nipple of the milk cow, the bacterial content in a milk product is reduced, and the quality of the milk product is improved.
(2) The isotridecanol polyoxyethylene ether, the polyether modified heptamethyltrisiloxane gemini silicon surfactant and the auxiliary surfactant are compounded, the auxiliary surfactant can prevent the isotridecanol polyoxyethylene ether from precipitating and precipitating on a medicinal bath liquid when the viscosity of the medicinal bath liquid is too high or the stabilizer is too much, the complexing effect on an iodine preparation is improved, the stability is improved, and the polyether modified heptamethyltrisiloxane gemini silicon surfactant is low in usage amount, so that the influence on the stability of a system is small, and the safety is high. The three components are used in a compounding way, so that the stability and the sterilization effect of the medicated bath liquid can be greatly improved.
(3) The polyether modified heptamethyltrisiloxane gemini silicon surfactant is compounded with isomeric tridecanol polyoxyethylene ether. Isomeric tridecanol polyoxyethylene ether can also improve the complex stability and the bactericidal effect of iodine preparation, and after isomeric tridecanol polyoxyethylene ether is compounded with polyether modified heptamethyltrisiloxane gemini silicon surface active agent, can also improve the condensation effect of polyether modified heptamethyltrisiloxane gemini silicon surface active agent, coagulate and fully disinfect inside and outside the nipple at the cow nipple, do not drip, not only can play this some bactericidal action before milk is extruded sooner, but also can play better guard action to the nipple before milk is extruded.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the embodiments or the description of the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a schematic diagram of the coagulation at different times of application example 15 (left slide) and comparative example 1 (right slide) of the present invention;
FIG. 2 is a schematic diagram of the agglomeration of application example 15 (left slide) and comparative example 7 (right slide) of the present invention at different times;
FIG. 3 is a schematic diagram of the coagulation of application example 15 (left slide) and comparative example 10 (right slide) of the present invention at different times.
Detailed description of the preferred embodiments
In order to make the technical solutions of the present invention better understood, the technical solutions of the present invention will be clearly and completely described below with reference to the embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The examples do not indicate specific experimental procedures or conditions, and can be performed according to the procedures or conditions of the conventional experimental procedures described in the prior art in the field. The reagents and other instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially.
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 0.5-5% of iodine preparation, 3-30% of isomeric tridecanol polyoxyethylene ether, 0.001-0.1% of organic silicon surfactant, 2-20% of auxiliary surfactant, 0-60% of auxiliary material and the balance of water.
It should be noted that, in the actual use process, corresponding auxiliary materials can be added according to the actual requirements to achieve the expected technical effect. Wherein the auxiliary materials include but not limited to one or more of wetting agent, stabilizer and pH regulator.
The wetting agent is one or more of glycerin, sorbitol, lanolin and the like, and mainly has the effects of moistening and preserving the skin on the surface of the breast of the cow, and reducing the stimulation to the skin.
The stabilizer is one or more of hydroxymethyl cellulose, carboxymethyl cellulose and xanthan gum, and the addition amount of the stabilizer is 0.1-2%. The stabilizer mainly has thickening effect on the whole medicinal bath liquid, and has the effect of preventing the medicinal bath liquid from being hung on the cow nipple.
In the invention, the iodine preparation comprises any one of elementary iodine, povidone iodine, iodine glycerol, potassium iodide and potassium iodate; iodine preparation is used as main component for sterilization and disinfection.
In the invention, the EO number of the isomeric tridecanol polyoxyethylene ether is 10-30. The isomeric tridecanol ethoxylates with EO numbers of 10 are preferred. The specific synergistic effect of the tridecyl structure and the isomeric structure of the isomeric tridecanol polyoxyethylene ether can improve the space stability of the obtained complex structure, and can improve the stability of a disinfectant system after compounding an auxiliary surfactant, thereby achieving the purposes of improving the stability of the disinfectant, reducing the consumption of iodine and prolonging the disinfection effect. The isomeric tridecanol polyoxyethylene ether is an isomer, so that precipitation and precipitation are easy to occur when the viscosity of a system is too high or a stabilizer is too much, and the quality of a product is influenced.
In the invention, the organosilicon surfactant is polyether modified heptamethyltrisiloxane gemini silicon surfactant, and the structure of the organosilicon surfactant is as follows:
In the invention, the auxiliary surfactant is one or more of fatty alcohol-polyoxyethylene ether, betaine, alkylphenol ethoxylates, fatty amine, phosphate, EO and PO block surfactants. Wherein the fatty alcohol-polyoxyethylene ether is preferably any one of fatty alcohol-polyoxyethylene ether AEO-3, fatty alcohol-polyoxyethylene ether AEO-10 and fatty alcohol-polyoxyethylene ether AEO-9.
The fatty amine in the present invention is preferably fatty amine polyoxyethylene ether 1815.
The EO and PO block surfactants of the invention are copolymers having an EO number of from 3 to 30, preferably the polyether PE6800 (ethylene oxide propylene oxide block copolymer) produced by BASF.
The invention also discloses a preparation method of the milk cow nipple medicated bath liquid, which comprises the following steps:
(1) Adding an iodine preparation and isomeric tridecanol polyoxyethylene ether into a reaction container, wherein the reaction temperature is 50-100 ℃, and the reaction time is 0.5-3h;
(2) Adding an auxiliary surfactant, an organic silicon surfactant, an auxiliary material and water into the reaction container in the step (1), and reacting for 0.5-3h at the reaction temperature of 50-100 ℃; and finally adding a pH regulator to regulate the pH value to 6-7, and reacting for 10-30min to obtain the cow nipple medicated bath liquid.
Method example 1
A preparation method of a cow nipple medicated bath liquid comprises the following steps:
(1) Adding elementary iodine and isomeric tridecanol polyoxyethylene ether into a reaction container, and reacting at the temperature of 50 ℃ for 3 hours;
(2) Adding an auxiliary surfactant, an organic silicon surfactant, an auxiliary material and water into the reaction container in the step (1), and reacting for 0.5h while keeping the reaction temperature at 100 ℃; and finally, adding a pH regulator to regulate the pH value to 7, and reacting for 30min to obtain the cow nipple medicated bath liquid.
Method example 2
A preparation method of a cow nipple medicated bath liquid comprises the following steps:
(1) Adding elementary iodine and isomeric tridecanol polyoxyethylene ether into a reaction container, and reacting at the temperature of 100 ℃ for 0.5h;
(2) Adding an auxiliary surfactant, an organic silicon surfactant, an auxiliary material and water into the reaction container in the step (1), and reacting for 3 hours at the reaction temperature of 50 ℃; and finally, adding a pH regulator to regulate the pH value to 7, and reacting for 30min to obtain the cow nipple medicated bath liquid.
Method example 3
A preparation method of a cow nipple medicated bath liquid comprises the following steps:
(1) Adding elementary iodine and isomeric tridecanol polyoxyethylene ether into a reaction container, and reacting at the temperature of 80 ℃ for 2 hours;
(2) Adding an auxiliary surfactant, an organic silicon surfactant, an auxiliary material and water into the reaction container in the step (1), and reacting for 2 hours at the reaction temperature of 80 ℃; and finally, adding a pH regulator to regulate the pH value to 6, and reacting for 20min to obtain the cow nipple medicated bath liquid.
Application example 1
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 10 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.1 per mill polyether modified heptamethyltrisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant fatty alcohol polyoxyethylene ether AEO-3, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example a medicated bath solution for cow teats was prepared according to the method of example 3.
Application example 2
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 8 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.1 per mill polyether modified heptamethyltrisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant fatty alcohol polyoxyethylene ether AEO-10, 15 percent of glycerin, 15 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 3
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 1 percent of elementary iodine and 6 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.02 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant fatty alcohol polyoxyethylene ether AEO-10,8 percent of glycerin, 4 percent of sorbitol, 0.2 percent of hydroxymethyl cellulose and the balance of water;
this example a medicated bath solution for cow teats was prepared according to the method of example 3.
Application example 4
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 14 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.05 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant fatty alcohol polyoxyethylene ether AEO-10, 10 percent of glycerin, 5 percent of lanolin, 0.1 percent of xanthan gum and the balance of water;
this example a medicated bath solution for cow teats was prepared according to the method of example 3.
Application example 5
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 1.5 percent of elementary iodine and 10 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.01 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant polyether PE6800, 12 percent of glycerol, 3 percent of sorbitol, 0.5 percent of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 6
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 3 percent of elementary iodine and 16 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.001 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 5 percent of auxiliary surfactant fatty amine polyoxyethylene ether 1815, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example a medicated bath solution for cow teats was prepared according to the method of example 3.
Application example 7
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 4 percent of elementary iodine and 20 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.05 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 6 percent of auxiliary surfactant dodecyl dimethyl betaine, 8 percent of glycerin, 6 percent of lanolin, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 8
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 5 percent of elementary iodine and 20 percent of isomeric tridecanol polyoxyethylene ether 20 (C) 13 H 27 O(CH 2 CH 2 O) 20 H) 0.06% o polyether modified heptamethyl trisiloxane gemini silicon surfactant, 10% of auxiliary surfactant fatty alcohol polyoxyethylene ether AEO-9, 15% of glycerin, 0.05% of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 9
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.06 thousandth of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 5 percent of auxiliary surfactant nonylphenol polyoxyethylene ether, 10 percent of glycerin, 5 percent of lanolin, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example a medicated bath solution for cow teats was prepared according to the method of example 3.
Application example 10
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 1.5 percent of elementary iodine and 10 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.01 per mill of polyether modified heptamethyl trisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant potassium dodecyl phosphate, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 11
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 12 (C) 13 H 27 O(CH 2 CH 2 O) 12 H) 0.01 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant potassium dodecyl phosphate, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 12
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 15 (C) 13 H 27 O(CH 2 CH 2 O) 15 H) 0.01 per mill of polyether modified heptamethyl trisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant potassium dodecyl phosphate, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example a medicated bath solution for cow teats was prepared according to the method of example 3.
Application example 13
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 20 (C) 13 H 27 O(CH 2 CH 2 O) 20 H) 0.01 per mill polyether modified heptamethyltrisiloxane gemini silicon surfactant, 2% of auxiliary surfactant potassium dodecyl phosphate, 10% of glycerol, 5% of sorbitol, 0.1% of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 14
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 30 (C) 13 H 27 O(CH 2 CH 2 O) 30 H) 0.01 per mill of polyether modified heptamethyl trisiloxane gemini silicon surfactant, 2 percent of auxiliary surfactant potassium dodecyl phosphate, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example is a cow teat dip prepared according to method example 3.
Application example 15
The medicated bath liquid for the nipples of the dairy cows comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.01 per mill of polyether modified heptamethyl trisiloxane gemini silicon surfactant, 4 percent of auxiliary surfactant potassium dodecyl phosphate, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water;
this example a medicated bath solution for cow teats was prepared according to the method of example 3.
Comparative example 1
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 4% of potassium dodecyl phosphate, 10% of glycerol, 5% of sorbitol, 0.1% of hydroxymethyl cellulose and the balance of water;
comparative example 2
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.01 per mill polyether modified heptamethyl trisiloxaneGemini silicon surfactant, 10% of glycerol, 5% of sorbitol, 0.1% of hydroxymethyl cellulose and the balance of water.
Comparative example 3
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine, 0.01 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 4 percent of auxiliary surfactant potassium dodecyl phosphate, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water.
Comparative example 4
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine, 0.01 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant and 4 percent of alkyl glycoside C 8 /C 10 10% of glycerol, 5% of sorbitol, 0.1% of hydroxymethyl cellulose and the balance of water.
Comparative example 5
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine, 0.01 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 4 percent of auxiliary surfactant fatty alcohol polyoxyethylene ether AEO-3, 10 percent of glycerin, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water.
Comparative example 6
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine, 0.01 per mill of polyether modified heptamethyltrisiloxane gemini silicon surfactant, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water.
Comparative example 7
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine, 12 percent of fatty alcohol-polyoxyethylene ether AEO-10,0.01 per thousand polyether modified heptamethyltrisiloxane gemini silicon surfactant, 4 percent of auxiliary surfactant potassium dodecyl phosphate, 10 percent of glycerol, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water.
Comparative example 8
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of elementary iodine and 12 percent of isomeric tridecanol polyoxyethylene ether 10 (C) 13 H 27 O(CH 2 CH 2 O) 10 H) 0.01 per mill polyether modified heptamethyl trisiloxane gemini silicon surfactant and 4 percent alkyl glycoside C 8 /C 10 10% of glycerol, 5% of sorbitol, 0.1% of hydroxymethyl cellulose and the balance of water.
Comparative example 9
The milk cow nipple medicated bath liquid comprises the following components in percentage by weight: 2 percent of simple substance iodine, 16 percent of fatty alcohol-polyoxyethylene ether AEO-3, 10 percent of glycerin, 5 percent of sorbitol, 0.1 percent of hydroxymethyl cellulose and the balance of water.
Comparative example 10
A 2% medicated bath solution is commercially available. The product is prepared from Dibao of a Czochralski method, the iodine content is 2%, and the formula does not contain an organic silicon surfactant (polyether modified heptamethyltrisiloxane gemini silicon surfactant).
The cow teat dip solutions of comparative examples 1 to 9 were prepared according to method example 3.
Iodine complexation and stability test
1. Iodine complexation and stability testing
The iodine content of the bath liquids obtained in application examples 1 to 15 and comparative examples 1 to 10 was measured according to the starch identification and iodine content measurement methods of povidone iodine in pharmacopoeia, and the results are shown in table 1:
TABLE 1 iodine content and stability in each bath liquid
As can be seen from the application example 15 and the comparative example 1, the initial content of the comparative example 1 is basically the same as that of the application example 15, and the fact that the isotridecanol polyoxyethylene ether is compounded with the auxiliary surfactant can improve the iodine complexation is demonstrated. By applying example 15 and comparative example 2, it can be seen that the initial content of iodine is low in comparative example 2 without adding an auxiliary surfactant, and the isomeric tridecanol polyoxyethylene ether is relatively weak in stability and is easy to precipitate and separate out due to the fact that no auxiliary surfactant is compounded in comparative example 2. As can be seen from application example 15, comparative example 1, comparative example 2 and comparative example 8, the isotridecanol polyoxyethylene ether in application example 15 of the invention can improve the complexation of iodine by compounding with an auxiliary surfactant.
In comparative examples 3, 4, 5 and 6, the isotridecanol polyoxyethylene ether is free from the problems of precipitation and precipitation, and shows that the isotridecanol polyoxyethylene ether is a main component for iodine complexation and plays a main role in iodine complexation and stability. Due to the fact that the auxiliary surfactant is not compounded, the relative stability of the isomeric tridecanol polyoxyethylene ether is weak. By comparing the application example 15 with the comparative examples 7 and 9, the compound complexing system of the isomeric tridecanol polyoxyethylene ether has obvious complexing stability advantage compared with the compound complexing system of the polyoxyethylene ether; in contrast, application example 15 and comparative example 10 show that application example 15 also has a distinct complexing stability advantage compared to the commercial bath products.
As can be seen from comparative examples 5 and 9, the fatty alcohol-polyoxyethylene ether added in comparative example 5 is less, and therefore, precipitation occurs; the fatty alcohol-polyoxyethylene ether added in the comparative example 9 is more, and the complexation of iodine has certain advantages, but compared with the application example 15, the stability of the fatty alcohol-polyoxyethylene ether to iodine is obviously reduced in a long-term storage process, and the complexation and long-term stability of isomeric tridecanol polyoxyethylene ether to iodine have good effects.
2. Temperature resistance test of medicated bath solution
The bath solutions of application examples 1 to 15 were subjected to high temperature resistance and low temperature resistance stability tests, respectively, wherein the high temperature resistance (120 ℃) was 4 hours and the low temperature resistance (-20 ℃) was 4 hours, and the obtained results are shown in table 2;
TABLE 2 results of temperature resistance test
As can be seen from Table 2, the medicated bath solutions of application examples 1-15 all reached their standards. Moreover, as can be seen from the results of comparative example 2, the medicated bath liquid of the present invention could not be stabilized in a high-temperature or low-temperature state when formulated without the addition of a cosurfactant. As can be seen from comparative examples 3-6, the drug bath solution has no stability at high temperature and low temperature when no isomeric tridecanol polyoxyethylene ether is added, so that the addition of isomeric tridecanol polyoxyethylene ether can obviously improve the temperature resistance of the drug bath solution as can be seen from application examples 1-15 and comparative examples 3-6.
3. Cohesion test
3.1, respectively taking the medicated bath liquids of the application examples 1 to 15 and the comparative examples 1 to 10 as samples, respectively placing the samples in beakers, respectively, vertically inserting the skin simulation finger models into the samples by using the skin simulation finger models, keeping the height of the samples in the beakers to be not less than 50mm, then vertically taking out the skin simulation finger models, observing the dropping condition of the medicated bath liquids, and finding that the medicated bath liquids can be gathered at the tail ends of the fingers within 1min and do not drop. The medicinal bath liquid has the effects of quick coagulation and no dripping when being applied to the cow nipple, can achieve quick and efficient sterilization when being applied to the cow nipple, and can achieve the effect of long-acting protection on the cow nipple.
3.2, taking the medical bath solution in the application examples 1-15 and the comparative examples 1-10 as samples, respectively, taking 2ml of each sample as a sample to be tested, uniformly spreading the sample to be tested on an adhesive glass slide (25 mm in width and 75mm in height) which is horizontally placed, and observing the test phenomenon to obtain the results shown in Table 3;
TABLE 3 cohesion property
As can be seen from the data in table 3 and fig. 1-3, the systems do not have an agglomeration effect in the absence of gemini silicon surfactants in comparative example 1 and comparative example 9. As can be seen from application example 15 and comparative example 7, when the copolymer is compounded with fatty alcohol-polyoxyethylene ether, the gathering effect of comparative example 7 is also poor. The comparative example 10 is a conventional commercial product, and a nonionic surfactant is generally added into the commercial product, but a polyether modified heptamethyltrisiloxane dimeric silicon surfactant is not added, so that the gathering effect is poor.
It can be seen from application example 15 and comparative example 8 that the gemini silicon surfactant does not produce a coagulation effect in a system obtained by compounding with all surfactants, and a good coagulation effect can be achieved only by compounding with the isomeric tridecanol polyoxyethylene ether and the auxiliary surfactant of the present invention.
4. Determination of Breast bacteria killing Effect before and after milk cow infiltration
The method comprises the steps of taking the medicinal bath liquid obtained in the application example 15, the comparative example 1, the comparative example 7, the comparative example 8, the comparative example 9, the comparative example 10 and a blank control group (distilled water) as samples to carry out a breast sterilization experiment, dividing the cows into 7 groups, selecting 30 cows in the lactation period for each group, respectively infiltrating the nipples by the samples, taking the medicinal bath liquid away after the infiltration time is 5s and 5s, staying the medicinal bath liquid on the surfaces of the breasts of the cows for 3min, and then cleaning the medicinal bath liquid by distilled water. Before infiltration, respectively use the aseptic cotton swab to sample at same nipple after the washing, cultivate and the colony count statistics according to disinfection technical specification mode, later calculate the average value of the bactericidal effect of dipping liquid to the nipple.
The calculation formula is as follows:
the results obtained are shown in table 4:
TABLE 4 cow udder sterilization test results
As can be seen from table 4, the bath liquid of application example 15 of the present invention has better bactericidal effect than that of comparative examples 1, 8 and 9; compared with the comparative example 7, the isomeric tridecanol polyoxyethylene ether system in the application example 15 of the invention has better bactericidal effect compared with other systems. Application example 15 of the present invention compared with comparative commercially available bath solution example 10, the bath solution of application example 15 of the present invention has a more excellent bactericidal effect as a bath solution before milking.
5, the protective effect of the medicated bath liquid on the nipples of the dairy cows
The protection of the mastitis of the cows was observed by conducting a teat protection test using application example 15, comparative example 1, comparative example 8, comparative example 9, comparative example 10 and a blank group (distilled water), dividing the cows into 6 groups, selecting 60 cows in the lactation period for each group, and performing an experimental period of 30 days, with the results shown in table 5:
TABLE 5 cow breast protection results
As can be seen from the application example 15 and the comparative examples 1, 8 and 9, the medicated bath liquid with good coagulation effect of the application example 15 of the invention has better sterilization effect and better protection effect; as can be seen from comparison of application example 15 with comparative example 10, the application example 15 of the present invention has more excellent effect of preventing occult mastitis than the commercially available medicated bath solution.
Reference herein to "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment can be included in at least one embodiment of the invention. The appearances of the phrase in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments. It is explicitly and implicitly understood by one skilled in the art that the embodiments described herein can be combined with other embodiments.
Finally, it should be noted that: the embodiment of the present invention is disclosed only as a preferred embodiment of the present invention, which is only used for illustrating the technical solutions of the present invention and not for limiting the same; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those skilled in the art; the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (8)
1. A medicated bath liquid for cow nipples is characterized in that: comprises the following components in percentage by weight: 0.5-5% of iodine preparation, 3-30% of isomeric tridecanol polyoxyethylene ether, 0.001-0.1% of organic silicon surfactant, 2-20% of auxiliary surfactant, 0-60% of auxiliary material and the balance of water.
2. The cow nipple medicated bath of claim 1, wherein: the EO number in the isomeric tridecanol polyoxyethylene ether is 10-30.
3. The milk cow nipple medicated bath liquid of claim 1, wherein: the organic silicon surfactant is polyether modified heptamethyl trisiloxane gemini silicon surfactant.
4. The milk cow nipple medicated bath liquid of claim 1, wherein: the auxiliary surfactant is one or more of fatty alcohol-polyoxyethylene ether, betaine, alkylphenol ethoxylates, fatty amine, phosphate ester, EO and PO block surfactants.
5. The milk cow nipple medicated bath liquid of claim 4, wherein: the fatty alcohol-polyoxyethylene ether in the auxiliary surfactant is any one of fatty alcohol-polyoxyethylene ether AEO-3, fatty alcohol-polyoxyethylene ether AEO-10 and fatty alcohol-polyoxyethylene ether AEO-9;
the EO and PO block surfactants are copolymers with EO numbers of 3-30.
6. The milk cow nipple medicated bath liquid of claim 1, wherein: the auxiliary materials comprise one or more of a wetting agent, a stabilizing agent and a pH regulator.
7. The cow nipple medicated bath of claim 6, wherein: the stabilizer is one or more of hydroxymethyl cellulose, carboxymethyl cellulose and xanthan gum.
8. A method for preparing a medicated bath solution for cow teats as defined in any one of claims 1 to 7, wherein: the method comprises the following steps:
(1) Adding an iodine preparation and isomeric tridecanol polyoxyethylene ether into a reaction container, wherein the reaction temperature is 50-100 ℃, and the reaction time is 0.5-3h;
(2) Adding an auxiliary surfactant, an organic silicon surfactant, an auxiliary material and water into the reaction container in the step (1), and reacting for 0.5-3h while keeping the reaction temperature at 50-100 ℃; and finally adding a pH regulator, and reacting for 10-30min to obtain the cow nipple medicated bath liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310146156.XA CN115869260B (en) | 2023-02-22 | 2023-02-22 | Dairy cow nipple medicated bath liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310146156.XA CN115869260B (en) | 2023-02-22 | 2023-02-22 | Dairy cow nipple medicated bath liquid and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115869260A true CN115869260A (en) | 2023-03-31 |
| CN115869260B CN115869260B (en) | 2023-05-12 |
Family
ID=85761495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310146156.XA Active CN115869260B (en) | 2023-02-22 | 2023-02-22 | Dairy cow nipple medicated bath liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115869260B (en) |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534266A (en) * | 1994-06-20 | 1996-07-09 | Devtech Corporation | Bovine teat dip |
| US5720984A (en) * | 1994-06-20 | 1998-02-24 | Devtech Corporation | Bovine teat dip |
| JPH11155404A (en) * | 1997-12-01 | 1999-06-15 | Nippon Zenyaku Kogyo Kk | Germicidal disinfectant for nipple of milk cow |
| US20050031705A1 (en) * | 2003-08-04 | 2005-02-10 | Ko Manufacturing, Inc. | Topical veterinary compositions and methods for the treatment and prevention of infection |
| US20120295940A1 (en) * | 2010-11-14 | 2012-11-22 | Noble Ion, Llc | Compositions for treating mastitis |
| CN103908926A (en) * | 2014-03-18 | 2014-07-09 | 五邑大学 | A dimeric polyoxyethylene ether trisiloxane surfactant and a preparing method thereof |
| JP2016036340A (en) * | 2014-08-07 | 2016-03-22 | 株式会社トクヤマ | Nipple protecting material for livestock and method for protecting nipples of livestock |
| CN105596235A (en) * | 2016-01-11 | 2016-05-25 | 西安汉隆化工科技有限公司 | Novel milk cow nipple medicated bath solution and preparing method thereof |
| CN105687229A (en) * | 2016-01-11 | 2016-06-22 | 西安汉隆化工科技有限公司 | Film forming type cow nipple protective agent and preparation method thereof |
| CN106236772A (en) * | 2016-08-30 | 2016-12-21 | 北京安洁康生物科技有限公司 | Pasture disinfectant for nipples of dairy cows and its preparation method and application |
| CN107809908A (en) * | 2015-06-23 | 2018-03-16 | 艺康美国股份有限公司 | For applying the aqueous antimicrobial film-forming composition for carrying out nipple treatment by spraying |
| CN108714138A (en) * | 2018-06-11 | 2018-10-30 | 佛山市南海东方澳龙制药有限公司 | Betagen Solution and preparation method thereof |
| CN110013472A (en) * | 2019-04-30 | 2019-07-16 | 扬州大学 | A kind of milk cow teat film-forming medicated bath agent, its preparation method and its use method |
| CN110464738A (en) * | 2019-09-26 | 2019-11-19 | 成都科宏达科技有限公司 | A kind of compound disinfectant preventing cow breast disease |
| CN111280175A (en) * | 2020-03-06 | 2020-06-16 | 威海诺葳信和新材料有限公司 | Multi-point quaternary ammonium salt modified organic silicon copolymer type antibacterial agent and preparation method thereof |
| CN114698634A (en) * | 2022-03-09 | 2022-07-05 | 四川科宏达集团有限责任公司 | Application of isomeric tridecanol polyoxyethylene ether in iodine disinfectant and application method thereof |
-
2023
- 2023-02-22 CN CN202310146156.XA patent/CN115869260B/en active Active
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534266A (en) * | 1994-06-20 | 1996-07-09 | Devtech Corporation | Bovine teat dip |
| US5720984A (en) * | 1994-06-20 | 1998-02-24 | Devtech Corporation | Bovine teat dip |
| JPH11155404A (en) * | 1997-12-01 | 1999-06-15 | Nippon Zenyaku Kogyo Kk | Germicidal disinfectant for nipple of milk cow |
| US20050031705A1 (en) * | 2003-08-04 | 2005-02-10 | Ko Manufacturing, Inc. | Topical veterinary compositions and methods for the treatment and prevention of infection |
| US20120295940A1 (en) * | 2010-11-14 | 2012-11-22 | Noble Ion, Llc | Compositions for treating mastitis |
| CN103908926A (en) * | 2014-03-18 | 2014-07-09 | 五邑大学 | A dimeric polyoxyethylene ether trisiloxane surfactant and a preparing method thereof |
| JP2016036340A (en) * | 2014-08-07 | 2016-03-22 | 株式会社トクヤマ | Nipple protecting material for livestock and method for protecting nipples of livestock |
| CN107809908A (en) * | 2015-06-23 | 2018-03-16 | 艺康美国股份有限公司 | For applying the aqueous antimicrobial film-forming composition for carrying out nipple treatment by spraying |
| CN105687229A (en) * | 2016-01-11 | 2016-06-22 | 西安汉隆化工科技有限公司 | Film forming type cow nipple protective agent and preparation method thereof |
| CN105596235A (en) * | 2016-01-11 | 2016-05-25 | 西安汉隆化工科技有限公司 | Novel milk cow nipple medicated bath solution and preparing method thereof |
| CN106236772A (en) * | 2016-08-30 | 2016-12-21 | 北京安洁康生物科技有限公司 | Pasture disinfectant for nipples of dairy cows and its preparation method and application |
| CN108714138A (en) * | 2018-06-11 | 2018-10-30 | 佛山市南海东方澳龙制药有限公司 | Betagen Solution and preparation method thereof |
| CN110013472A (en) * | 2019-04-30 | 2019-07-16 | 扬州大学 | A kind of milk cow teat film-forming medicated bath agent, its preparation method and its use method |
| CN110464738A (en) * | 2019-09-26 | 2019-11-19 | 成都科宏达科技有限公司 | A kind of compound disinfectant preventing cow breast disease |
| CN111280175A (en) * | 2020-03-06 | 2020-06-16 | 威海诺葳信和新材料有限公司 | Multi-point quaternary ammonium salt modified organic silicon copolymer type antibacterial agent and preparation method thereof |
| CN114698634A (en) * | 2022-03-09 | 2022-07-05 | 四川科宏达集团有限责任公司 | Application of isomeric tridecanol polyoxyethylene ether in iodine disinfectant and application method thereof |
Non-Patent Citations (2)
| Title |
|---|
| WILLIAM SMITS 等: "选择奶牛乳头药浴液的核心原则", 中国乳业 * |
| 尹丹娜 等: "聚醚改性三硅氧烷表面活性剂的合成与表征", 化工学报 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115869260B (en) | 2023-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100284081B1 (en) | Iodine Barrier Nipple Dip | |
| CN108714138B (en) | Povidone-iodine solution and preparation method thereof | |
| CN105687229B (en) | A kind of film-forming type mammilla of milk cattle protective agent and preparation method thereof | |
| CN108653201B (en) | Drip-proof povidone iodine solution and preparation method thereof | |
| CN106236772B (en) | Pasture disinfectant for nipples of dairy cows and its preparation method and application | |
| CN104622792A (en) | Film-forming papilla medicated bath preparation used for controlling recessive mastitis of dairy cattle | |
| CN110420257B (en) | Composite cow nipple medicated bath liquid and preparation method thereof | |
| CN105106177A (en) | Film-forming agent capable of preventing cow mastitis and preparation method thereof | |
| CN110013472A (en) | A kind of milk cow teat film-forming medicated bath agent, its preparation method and its use method | |
| CN101628006B (en) | Composition for disinfecting nipple skins of dairy cows | |
| CN113080207B (en) | Process for preparing disinfectant | |
| CN115869260A (en) | Milk cow nipple medicated bath liquid and preparation method thereof | |
| Philpot et al. | Hygiene in the prevention of udder infections. V. Efficacy of teat dips under experimental exposure to mastitis pathogens | |
| CN106798749B (en) | Povidone-iodine film-forming disinfectant and preparation method and application thereof | |
| CN113632803B (en) | Quaternary ammonium salt complex iodine disinfectant and preparation method thereof | |
| CN102552317B (en) | Iodine glycerol nipple infusion and preparation method thereof | |
| DK167909B1 (en) | GERMICIDT ANIMAL PATH TREATMENT CONCENTRATE, GERMICIDT ANIMAL PATH TREATMENT AND USE OF A GERMICID FOR THE PREPARATION OF A MEDICINE AGAINST BOVIN SUMMARY | |
| CN108403671B (en) | Povidone-iodine solution and preparation method thereof | |
| JPH11155404A (en) | Germicidal disinfectant for nipple of milk cow | |
| CN110711204A (en) | Iodine-glycerol nipple infusion and preparation method thereof | |
| RU2583932C1 (en) | Agent for post-milking treatment of cows teats | |
| CN117919272A (en) | Cow nipple front medicinal bath lotion and preparation method thereof | |
| CN115350270B (en) | Lysostaphin emulsion protecting film preparation and preparation process thereof | |
| CN113288913A (en) | Povidone iodine solution and preparation method thereof | |
| CN106138091A (en) | A kind of pharmaceutical composition preventing and treating bovine mastitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No. 17, 2nd Floor, Building A, Building 1, No. 1480 Tianfu Avenue North Section, Chengdu High tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu, Sichuan Province, 610000 Patentee after: Chengdu kehongda Chemical Co.,Ltd. Country or region after: China Patentee after: CHENGDU KEHONGDA TECHNOLOGY Co.,Ltd. Address before: No. 506, 507, 508, Floor 5, Unit 1, Building 1, No. 777, North Yizhou Avenue, Chengdu Hi tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu 610000 Patentee before: Sichuan kehongda Group Co.,Ltd. Country or region before: China Patentee before: CHENGDU KEHONGDA TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 21st Floor, Building 4, No. 11 Yangliu Avenue, Huayuan Street, Xinjin District, Chengdu City, Sichuan Province 610000 Patentee after: Chengdu kehongda Chemical Co.,Ltd. Country or region after: China Patentee after: CHENGDU KEHONGDA TECHNOLOGY Co.,Ltd. Address before: No. 17, 2nd Floor, Building A, Building 1, No. 1480 Tianfu Avenue North Section, Chengdu High tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu, Sichuan Province, 610000 Patentee before: Chengdu kehongda Chemical Co.,Ltd. Country or region before: China Patentee before: CHENGDU KEHONGDA TECHNOLOGY Co.,Ltd. |